Nexus Clinical Research was founded in 2004 by Dr. Ian Landells, a leading Dermatologist, and Dr. Majed Khraishi, a leading Rheumatologist, with a mandate to “provide tomorrow’s therapies today”, employing internationally leading standards to benefit the health of Newfoundlanders and Labradorians, and the world.
The company is recognized as one of the top research facilities in Canada with over 160 clinical trials completed. Nexus participates in Phase I, II, III and IV clinical trials involving Adult and Paediatric Dermatology, Rheumatology and some general practice. However, Nexus has differentiated itself by designing and implementing its own trials in order to advance knowledge of, and effective treatment and prevention of, specialty disease areas. Some of these “home grown” studies, in psoriatic arthritis for example, are breaking ground in understanding these diseases. Multiple reports about the initial results from these studies have been already published in major meetings. It has also invested heavily in infrastructure, providing onsite laboratory services; ultrasounds, EKGs, IV infusions, clinical photography and subcutaneous and IM injections for prescribed medications.
Nexus’ leading position is partially attributable to the founder population in Newfoundland, its focus on and access to the highest quality data, the high prevalence of specific disease in the province and the widespread knowledge and acceptance of clinical research by patients and practitioners in the province. Its key advantages are the founders; Dr. Landells and Dr. Khraishi and the highly trained, specialized personnel that the company employs. Both physicians hold seats on many national and international advisory boards and are established as leading specialists in their respective fields. They have also been highly successful in building partnerships for the purposes of advancing treatment, knowledge and the prevention of disease, as well as creating a thriving advanced medicine industry in this province. Nexus is also becoming a diversified biotechnology company.
Its plans include the expansion of current facilities to other areas of the province in order to conduct clinical research and then on to other major centres in Atlantic Canada. Additionally, Nexus is developing advanced communication technology tools that will become common and dominant in the diagnosis and early stage detection of disease. These tools will also greatly advance treatment by identifying potential co-morbidities and causal factors, and contribute to the streamlining of public healthcare through prioritization of patients and minimization of various cost impacts. Through partnerships, Nexus will also be delivering advanced diagnostics, the latest medicines and unprecedented access to cutting edge healthcare.